featured
Health-Related Quality of Life in Patients With Microsatellite Instability–High or Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-Line Pembrolizumab vs Chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Health-Related Quality of Life in Patients With Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer Treated With First-Line Pembrolizumab Versus Chemotherapy (KEYNOTE-177): An Open-Label, Randomised, Phase 3 Trial
Lancet Oncol 2021 Apr 01;[EPub Ahead of Print], T Andre, M Amonkar, JM Norquist, KK Shiu, TW Kim, BV Jensen, LH Jensen, CJA Punt, D Smith, R Garcia-Carbonero, I Sevilla, C De La Fouchardiere, F Rivera, E Elez, LA Diaz, T Yoshino, E Van Cutsem, P Yang, M Farooqui, DT LeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.